River Global Investors LLP Has $757,000 Position in Kenvue Inc. (NYSE:KVUE)

River Global Investors LLP lessened its holdings in Kenvue Inc. (NYSE:KVUE) by 26.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 35,418 shares of the company’s stock after selling 12,613 shares during the period. River Global Investors LLP’s holdings in Kenvue were worth $757,000 as of its most recent SEC filing.

Several other large investors have also recently bought and sold shares of KVUE. Concurrent Investment Advisors LLC boosted its stake in shares of Kenvue by 131.9% during the 3rd quarter. Concurrent Investment Advisors LLC now owns 53,517 shares of the company’s stock valued at $1,238,000 after buying an additional 30,438 shares during the period. Graypoint LLC purchased a new stake in shares of Kenvue during the third quarter worth $233,000. Principal Financial Group Inc. boosted its position in Kenvue by 3.2% during the third quarter. Principal Financial Group Inc. now owns 2,364,451 shares of the company’s stock valued at $54,690,000 after purchasing an additional 73,542 shares during the last quarter. CWA Asset Management Group LLC purchased a new position in Kenvue in the third quarter valued at about $307,000. Finally, Galvin Gaustad & Stein LLC acquired a new position in Kenvue in the 3rd quarter worth about $214,000. 97.64% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts recently commented on the company. Piper Sandler boosted their price target on Kenvue from $24.00 to $27.00 and gave the company an “overweight” rating in a research note on Monday, February 24th. UBS Group decreased their target price on shares of Kenvue from $23.00 to $21.00 and set a “neutral” rating for the company in a research report on Friday, February 7th. Royal Bank of Canada restated a “sector perform” rating and set a $24.00 price target on shares of Kenvue in a report on Monday, February 3rd. Canaccord Genuity Group upped their price objective on shares of Kenvue from $24.00 to $29.00 and gave the stock a “buy” rating in a report on Wednesday. Finally, Barclays cut their target price on Kenvue from $23.00 to $21.00 and set an “equal weight” rating on the stock in a report on Friday, January 17th. One analyst has rated the stock with a sell rating, seven have given a hold rating and five have issued a buy rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $23.75.

Kenvue Stock Up 1.2 %

KVUE opened at $23.46 on Friday. The business has a 50 day moving average of $21.64 and a 200-day moving average of $22.33. The stock has a market capitalization of $44.83 billion, a price-to-earnings ratio of 44.25, a P/E/G ratio of 2.62 and a beta of 1.25. The company has a current ratio of 1.00, a quick ratio of 0.69 and a debt-to-equity ratio of 0.66. Kenvue Inc. has a 1-year low of $17.67 and a 1-year high of $24.46.

Kenvue (NYSE:KVUE) last issued its quarterly earnings results on Thursday, February 6th. The company reported $0.26 earnings per share for the quarter, meeting analysts’ consensus estimates of $0.26. Kenvue had a net margin of 6.66% and a return on equity of 20.97%. As a group, sell-side analysts anticipate that Kenvue Inc. will post 1.14 earnings per share for the current year.

Kenvue Announces Dividend

The company also recently declared a quarterly dividend, which was paid on Wednesday, February 26th. Shareholders of record on Wednesday, February 12th were issued a $0.205 dividend. The ex-dividend date of this dividend was Wednesday, February 12th. This represents a $0.82 annualized dividend and a yield of 3.50%. Kenvue’s dividend payout ratio (DPR) is 154.72%.

About Kenvue

Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.